CVD Supplementary Information

The following diagrams accompany the article from Network Health Digest  June/July issue 155 'Cardiovascular Disease: Hypertension Risk Factors' by Bogna Nicinska RD.

Figure 1: Approach to lowering cardiovascular risk through lipid modification current strategy and potential future
options (16)

Treatments in black are licensed to lower the specific lipid parameter, those in red are in development and not yet approved for use. apo-apolipoprotein. mAbs-monoclonal antibodies. CETP=cholesteryl ester transfer protein. EPA-eicosapentaenoic acid. ANGPTL3-angiopoietin-related protein (3). SPPARM-selective peproxisome proliferator-activated receptor-α modulator.
*Approved for homozygous familial hypercholesterolaemia.

Figure 2: Impact of specific lifestyle changes on lipid levels. The magnitude of the effect and the level of
evidence refer to the impact of each dietary modification on plasma levels of a specific lipoprotein class. (17)

+++=>10%, ++=5-10%, +=<5%, HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol;
TC = total cholesterol; TG = triglyceride